Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Parma
Clinical trial register · Italy

Clinical Trials in Parma, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 2843 Bologna 1305 Roma 1274 Naples 984 Rome 967
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca16 Azienda Ospedaliero-Universitaria di Parma14 Hoffmann-La Roche8 Bristol-Myers Squibb6 University of Parma5
Site location
Milan2843 Bologna1305 Roma1274 Naples984 Rome967
All 489 locations
Target enrolment
to

Trials with a site in Parma

141 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Not yet open
Chiesi Farmaceutici S.p.A.
Phase 3
700
Brescia, Brindisi, Genoa, Messina, Milan, Naples, Parma, Pisa
2026-11-16
Not yet open
Eli Lilly and Company
Phase 3
150
Florence, Modena, Novara, Parma, Roma
2026-09
Recruiting
Gruppo Oncologico Italiano di Ricerca Clinica
Observational
150
Bologna, Meldola, Mantua, Carpi, Modena, Sassuolo, Piacenza, Parma
2026-07-30
Not yet open
Air-in-Line Alarms During Antineoplastic Drug Infusion
NCT07718711Infusion Safety, Medication Safety, Antineoplastic Drug Administration, Air-in-Line Alarm
Associazione Italiana Infermieri di Area Oncologica
Observational
40
Parma, Rome, Lodi, Milan
2026-07-01
Recruiting
Fisiopoint Parma Physiotherapy
Observational
280
Parma
2026-06-23
Recruiting
Hoffmann-La Roche
Phase 2/3
650
Naples, Meldola, Parma, Aviano, Rome, Bergamo, Brescia, Milan
2026-05-21
Recruiting
Bristol-Myers Squibb
Phase 3
850
Naples, Ravenna, Aviano, Orbassano, Rome, Milan, Parma
2026-03-16
Not yet open
Interprofessional Collaboration in the Cardiac Intensive Care Unit (CICU): An Action-Research Training Project
NCT07360366Interprofessional Relations, Interprofessional Education, Attitude of Health Personnel, Intensive Care Units
Azienda Ospedaliero-Universitaria di Parma
Not applicable
60
Parma
2026-02-15
Recruiting
Azienda Ospedaliero-Universitaria di Parma
Observational
150
Parma
2026-02-10
Recruiting
AstraZeneca
Phase 3
1,100
Brescia, Catania, Florence, Lecco, Milan, Naples, Parma, Pisa
2025-12-29
Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Not applicable
1,260
Bari, Bologna, Catania, Ferrara, Milan, Novara, Palermo, Parma
2025-12-03
Recruiting
TrueLok Elevate PMCF Study
NCT07079774Wound of Skin, Ulcers, Soft Tissue Defect
Orthofix s.r.l.
Observational
153
Acquaviva delle Fonti, Parma, Roma, Tivoli, Palermo
2025-11-24
Recruiting
Boehringer Ingelheim
Phase 3
670
Aviano (PN), Bari, Brescia, Florence, Meldola (FC), Orbassano (TO), Padova, Parma
2025-11-07
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Ravenna, Aviano, Orbassano, Candiolo, Avellino, Milan, Naples, Parma
2025-11-05
Recruiting
Ciceri Fabio
Not applicable
62
Milan, Bari, Parma
2025-10-31
Recruiting
Azienda Ospedaliero-Universitaria di Parma
Not applicable
310
Parma, Bologna, Cuneo, Milan, Udine
2025-10-07
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Bari, Genoa, Rome, Pisa, Castelfranco Veneto, Milan, Naples, Parma
2025-09-30
Not yet open
Fondazione IRCCS San Gerardo dei Tintori
Not applicable
106
Brescia, Monza, Bergamo, Como, Genova, Milan, Padova, Parma
2025-09-01
Recruiting
Mario Negri Institute for Pharmacological Research
Phase 2
21
Brescia, Florence, Genova, Milan, Padova, Parma
2025-08-07
Recruiting
Celcuity Inc
Phase 3
1,180
Fano, Genova, Meldola, Milan, Modena, Naples, Parma, Pavia
2025-07-24
Recruiting
SLIT ABS: Study on Patients With Autoimmune Podocytopathy
NCT07516964Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, Focal Segmental Glomerulosclerosis (FSGS), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
Meyer Children's Hospital IRCCS
Not applicable
50
Bagno a Ripoli, Florence, Bologna, Genova, Parma, Pisa, Prato, Reggio Emilia
2025-06-10
Recruiting
Hyaluronic Acid and Polynucleotides in Ridge Preservation
NCT07099846Socket Preservation, Implant-supported Single Crowns, Hyaluronic Acid, CAD-CAM
University of Parma
Not applicable
40
Parma
2025-06-09
Active, closed
Sanofi
Phase 3
1,092
Rome, Bari, Foggia, Lecce, Milan, Parma
2025-05-22
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
450
Bologna, Milan, Padova, Parma, Torino
2025-05-19
Recruiting
Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients
NCT06861361Symptomatic Severe Aortic Stenosis
Ceric Sàrl
Not applicable
1,180
Mercogliano, Milan, Parma, Roma, San Donato Milanese
2025-05-15
Recruiting
Feasibility of a Multi-omics Platform for Hematological Malignancies
NCT07445438Myeloma Multiple, Chronic Leukemia, Acute Leukemia, Myeloproliferative Disorders
DrugFunctional tests
Azienda Ospedaliero-Universitaria di Parma
Not applicable
1,040
Parma
2025-03-31
Recruiting
Swedish Orphan Biovitrum
Phase 3
104
Catanzaro, Florence, Milan, Naples, Parma, Rome, Rozzano, Vicenza
2025-03-06
Recruiting
Summit Therapeutics
Phase 3
780
Rome, Bari, Bergamo, Milan, Orbassano, Parma, Peschiera del Garda
2025-02-27
Recruiting
Menarini Group
Phase 2
44
Bari, Bologna, Genoa, Parma, Rome, Torino
2025-02-18
Recruiting
Saliva and Extracellular Vesicles for Neurodegenerative Diseases
NCT06869135Neurodegenerative Diseases, Parkinson Disease, Alzheimer Disease, Parkinsonism
Fondazione Don Carlo Gnocchi ETS
Observational
242
Florence, Milan, Parma
2025-01-24
Recruiting
Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares
Observational
180
Parma
2024-12-15
Active, closed
PPM Services S.A.
Phase 3
400
Ancona, Florence, Genova, Parma, Pavia, Roma, Bologna, Catania
2024-12-05
Recruiting
Eli Lilly and Company
Phase 3
125
Florence, Modena, Novara, Parma, Roma, Verona
2024-11-18
Active, closed
Istituto Oncologico Veneto IRCCS
Phase 2
41
Bergamo, Roma, Rozzano, Aviano, Alessandria, Ferrara, Padova, Parma
2024-11-06
Recruiting
Société des Produits Nestlé (SPN)
Not applicable
104
Naples, Parma, Pisa, Rome, Turin
2024-10-25
Recruiting
The Sagittarius Trial
NCT06490536Colon Cancer Stage II, Colon Cancer Stage III
DrugsFolinic acid·Panitumumab·Pertuzumab·Temozolomide
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3
700
Biella, Brescia, Genova, Milan, Rozzano, Novara, Parma, Perugia
2024-10-22
Recruiting
Azienda Ospedaliero-Universitaria di Parma
Not applicable
40
Parma
2024-10-14
Recruiting
AstraZeneca
Phase 3
744
Bari, Milan, Misterbianco, Monza, Naples, Orbassano, Padova, Parma
2024-10-04
Active, closed
Hoffmann-La Roche
Phase 3
338
Bari, Parma, Rome, Genoa, Sassari, Florence, Pisa, Padova
2024-09-23
Recruiting
Olfactory Testing in Perinatal Asphyxia: Enhancing Risk Assessment
NCT06744244Mild Birth Asphyxia, Moderate Birth Asphyxia
University of Parma
Observational
30
Parma
2024-09-10
Active, closed
Pregnancy and Lactation- Associated Osteoporosis
NCT07031557Osteoporosis and Fracture Risk in Pregnant Women
Parma University Hospital
Observational
1,230
Parma
2024-09-09
Recruiting
Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma
NCT06749600Primary Ovarian Leiomyosarcoma
Azienda USL Reggio Emilia - IRCCS
Observational
30
Modena, Parma, Reggio Emilia, Avellino, Catania, Milan, Monza, Naples
2024-06-14
Active, closed
Azienda Ospedaliero-Universitaria di Parma
Observational
110
Parma
2024-05-23
Recruiting
AstraZeneca
Phase 3
582
Milan, Monza, Orbassano, Padova, Parma
2024-04-29
Active, closed
Merck Sharp & Dohme LLC
Phase 2
272
Rome, Milan, Florence, Parma
2024-04-10
Active, closed
AstraZeneca
Phase 3
2,554
Bologna, Catanzaro, Chiavari, Desio, Milan, Naples, Parma, Rozzano
2024-03-29
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Agrigento, Bologna, Brescia, Cagliari, Florence, Milan, Padova, Parma
2024-03-29
Recruiting
Centro di Riferimento Oncologico - Aviano
Phase 2
45
Aviano, Florence, Lido di Camaiore, Meldola, Monza, Padova, Parma, Perugia
2024-03-15
Recruiting
medac GmbH
Phase 3
277
Arezzo, Ferrara, Florence, Naples, Parma, Pisa
2024-02-27
Active, closed
Boehringer Ingelheim
Phase 3
428
Bari, Candiolo (TO), Catania, Naples, Parma, Roma, Varese
2024-02-09
Active, closed
TransThera Sciences (Nanjing), Inc.
Phase 3
200
Ancona, Candiolo, Meldola, Milan, Naples, Parma, Pisa, Rozzano
2023-12-20
Active, closed
Hoffmann-La Roche
Phase 3
1,050
Brindisi, Avellino, Naples, Bologna, Meldola, Parma, Aviano (PN), Udine
2023-12-11
Active, closed
AstraZeneca
Phase 3
863
Alessandria, Bari, Bergamo, Milan, Monza, Orbassano, Padova, Parma
2023-11-09
Recruiting
University of Parma
Not applicable
30
Parma
2023-10-25
Active, closed
AstraZeneca
Phase 3
895
Bari, Bergamo, Milan, Padova, Parma, Pavia, Ravenna, Roma
2023-10-24
Active, closed
Janssen Research & Development, LLC
Phase 3
684
Palermo, Parma, Roma, Rozzano
2023-10-12
Active, closed
Standardizing the Management of Patients With Coronary Microvascular Dysfunction
NCT06025994Coronary Artery Disease, Microvascular Angina, Microvascular Ischemia of Myocardium
Consorzio Futuro in Ricerca
Not applicable
123
Ferrara, Parma
2023-10-10
Recruiting
Acrotech Biopharma Inc.
Phase 3
504
Tricase, Milan, Meldola, Borgo Roma, Alessandria, Genova, Parma, Pavia
2023-10-04
Active, closed
Mario Negri Institute for Pharmacological Research
Phase 4
190
San Fermo della Battaglia, Brescia, Florence, Lecco, Lucca, Milan, Padova, Parma
2023-09-15
Recruiting
Azienda Ospedaliero-Universitaria di Parma
Not applicable
265
Parma
2023-09-05
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Florence, Meldola, Cremona, Milan, Parma, Ravenna
2023-07-31
Recruiting
Kartos Therapeutics, Inc.
Phase 2/3
268
Catania, Forlì, Genoa, Lecco, Lucca, Milan, Parma, Piacenza
2023-07-17
Recruiting
Diagnosis and Outcomes of Placental Accretism
NCT06833606Placenta Accreta
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
70
Bologna, Cesena, Forlì, Modena, Parma, Reggio Emilia, Rimini
2023-07-17
Active, closed
Hansa Biopharma AB
Phase 3
150
Padova, Parma
2023-07-03
Active, closed
Advancing Early Bone Health: New Frontiers for Osteoporosis Prevention
NCT06750523Low-Risk Pregnant Women at Full-Term Gestation, Healthy Fetal Population, Healthy Neonatal Population
University of Parma
Not applicable
200
Messina, Parma
2023-05-17
Active, closed
University Hospital of Ferrara
Not applicable
1,823
Bologna, Ferrara, Bolzano, Catanzaro, Cosenza, Baggiovara, Piacenza, Parma
2023-05-08
Active, closed
Phase III Study of AK112 for NSCLC Patients
NCT06396065Non-Squamous Non-small Cell Lung Cancer
DrugsIvonescimab·Pemetrexed·Carboplatin
Summit Therapeutics
Phase 3
420
Milan, Parma, Roma, Rome
2023-05-04
Active, closed
Novo Nordisk A/S
Phase 3
7,101
Chieti, Bari, Modena, Parma, Rome, San Donato Milanese (MI), Latina, Pavia
2023-03-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Rome, Bergamo, Milan, Naples, Florence, Peschiera del Garda, Parma
2023-02-06
Active, closed
Obsessive-Compulsive Disorder: Insight, Trauma, and Links to Schizophrenia Spectrum Disorders
NCT07092826Obsessive-Compulsive Disorder (OCD), Schizophrenia and Schizophrenia Spectrum Psychosis
Matteo Tonna
Observational
300
Parma
2023-02-01
Active, closed
AstraZeneca
Phase 3
1,350
Florence, Lecco, Messina, Naples, Orbassano, Padova, Parma, Peschiera del Garda
2022-12-29
Recruiting
Azienda Ospedaliero-Universitaria di Parma
Observational
326
Cremona, Florence, Milan, Abano Terme, Verona, Parma
2022-12-22
Recruiting
Pfizer
Phase 3
100
Genoa, Rozzano, Rome, Parma, Torino
2022-12-09
Active, closed
Celcuity Inc
Phase 3
701
Milan, Modena, Monza, Parma, Prato, Rome, Udine
2022-12-08
Active, closed
AstraZeneca
Phase 3
594
Aviano, Livorno, Meldola, Milan, Monza, Naples, Padova, Parma
2022-09-15
Active, closed
Daiichi Sankyo
Phase 3
586
Bari, Chieti, Lucca, Milan, Orbassano, Parma, Perugia, Roma
2022-07-08
Active, closed
Gilead Sciences
Phase 2
193
Brescia, Catania, Parma, Rome, Rozzano
2022-05-30
Recruiting
CardioPulmonary Resuscitation With Argon (CPAr) Trial
NCT05482945Cardiac Arrest, Out-Of-Hospital, Cardiac Arrest With Successful Resuscitation
Mario Negri Institute for Pharmacological Research
Phase 2
120
Genova, Monza, Milan, Parma, Pordenone, Reggio Emilia, Roma, Trento
2022-05-30
Recruiting
Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera
NCT06516406Myelofibrosis, Primary Myelofibrosis, Secondary Myelofibrosis
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
1,055
Cosenza, Reggio Calabria, Naples, Bologna, Ferrara, Parma, Piacenza, Ravenna
2022-05-06
Active, closed
Novo Nordisk A/S
Phase 3
153
Catania, Florence, Padova, Parma
2022-03-24
Recruiting
Azienda Ospedaliero-Universitaria di Parma
Not applicable
70
Parma
2022-03-15
Recruiting
Azienda Ospedaliero-Universitaria di Parma
Not applicable
100
Meldola, Bologna, Ferrara, Parma, Piacenza, Ravenna, Reggio Emilia, Rimini
2022-03-01
Active, closed
AstraZeneca
Phase 3
390
Bari, Catania, Florence, Genova, Milan, Naples, Padova, Parma
2022-02-21
Active, closed
AstraZeneca
Phase 3
1,051
Brescia, Florence, Lucca, Meldola, Orbassano, Parma, Pavia, Roma
2022-02-07
Recruiting
Fondazione Don Carlo Gnocchi ETS
Observational
600
Florence, Milan, Parma, Rovato
2022-01-12
Active, closed
Azienda Ospedaliero-Universitaria di Parma
Not applicable
100
Parma
2022-01-05
Recruiting
Italian Multicenter Database for Open Conversions After EVAR
NCT04299984Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm Enlargement
Azienda Ospedaliero-Universitaria di Parma
Observational
500
Parma
2022-01-01
Active, closed
Boston Scientific Corporation
Not applicable
500
Parma, Rome, Verona
2021-12-21
Active, closed
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016Relapsed/Refractory Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 2
222
Parma, Rome, Varese
2021-12-01
Active, closed
European Association of Urology Research Foundation
Observational
1,076
Bologna, Foggia, Parma
2021-11-19
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Aviano, Meldola, Milan, Parma, Ravenna, Roma, Verona
2021-11-17
Active, closed
AstraZeneca
Phase 3
454
Milan, Monza, Orbassano, Parma, Roma, Verona
2021-10-28
Recruiting
Bayer
Phase 1/2
400
Aviano, Milan, Orbassano, Parma, Roma, Rozzano, Verona
2021-10-25
Active, closed
Sophia Genetics SAS
Observational
4,000
Parma, Roma, Udine
2021-08-21
Active, closed
MedSIR
Phase 2
393
Bologna, Milan, Monza, Parma, Piacenza, Roma
2021-08-05
Recruiting
Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)
NCT07445984Chronic Leukemia, Acute Leukemia, Myeloproliferative Disorders, Lymphoproliferative Disorders
Azienda Ospedaliero-Universitaria di Parma
Not applicable
250
Parma
2021-07-28
Active, closed
Boehringer Ingelheim
Phase 1
554
Candiolo (TO), Naples, Parma
2021-07-02
Recruiting
EyeConic: Qualification for Cone-Optogenetics
NCT05294978Retinal Dystrophies
Institute of Molecular and Clinical Ophthalmology Basel
Observational
1,000
Parma
2021-07-01
Active, closed
Azienda USL Reggio Emilia - IRCCS
Observational
41
Parma
2021-07-01
Active, closed
University of Parma
Observational
52
Parma
2021-06-01
Recruiting
Poor Grade Aneurysmal Subarachnoid Hemorrhage Study Group
NCT04945603Subarachnoid Hemorrhage, Aneurysmal, Poor Grade Subarachnoid Hemorrhage
IRCCS San Raffaele
Observational
800
Bergamo, Bologna, Brescia, Lecce, Milan, Novara, Parma, Roma
2021-05-25
Active, closed
Bristol-Myers Squibb
Phase 3
681
Cremona, Florence, Meldola, Milan, Padova, Parma, Pavia, Roma
2021-05-21
Active, closed
Azienda USL Reggio Emilia - IRCCS
Observational
700
Reggio Emilia, Bologna, Ferrara, Forlì, Modena, Parma, Rimini
2021-05-10
Active, closed
Hoffmann-La Roche
Phase 3
746
Foggia, Naples, Parma, Rome, Bergamo, Milan, Mondovì (CN), Catania
2021-03-17
Active, closed
Hoffmann-La Roche
Phase 3
55
Naples, Parma, Milan, Florence
2021-02-04
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
277
Parma, Orbassano, Meldola, Milan, Rozzano
2021-02-02
Active, closed
AstraZeneca
Phase 3
1,371
Bergamo, Florence, Milan, Modena, Naples, Novara, Padova, Parma
2021-01-28
Active, closed
Galderma R&D
Phase 3
500
Catania, Chieti, Genova, L’Aquila, Modena, Naples, Parma, Perugia
2021-01-11
Active, closed
Bayer
Phase 4
654
Ferrara, Modena, Parma, Aviano, Rome, Genoa, Milan, Alessandria
2020-11-09
Active, closed
Hoffmann-La Roche
Phase 3
985
Naples, Parma, Rome, Genoa, Milan, Montichiari, Pozzilli, Palermo
2020-10-26
By invitation
Novo Nordisk A/S
Observational
60
Parma, Roma, Torino, Vicenza
2020-10-23
Active, closed
Bayer
Phase 3
402
Naples, Parma, Orbassano, Turin, Padova
2020-10-20
Active, closed
Exelixis
Phase 3
575
Meldola, Rozzano, Sondrio, Trento, Ancona, Florence, Milan, Parma
2020-10-19
Active, closed
Hoffmann-La Roche
Phase 1/2
210
Parma, Bergamo, Magnago
2020-09-03
Active, closed
Hoffmann-La Roche
Phase 2/3
325
Parma, Brescia, Milan, Bagno a Ripoli, Padova
2020-01-29
Active, closed
Takeda
Phase 3
354
Naples, Meldola, Milan, Orbassano, Aviano, Pisa, Parma, Ravenna
2020-01-10
Active, closed
Bristol-Myers Squibb
Phase 3
461
Forlì, Milan, Parma
2019-11-05
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
NCT04221035High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
DrugsDinutuximab Beta·Vindesine·Cyclophosphamid·Thiotepa
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
800
Bari, Brescia, Catania, Florence, Genova, Modena, Parma, Pavia
2019-11-05
Active, closed
ETOP IBCSG Partners Foundation
Phase 3
405
Aviano, Bergamo, Brindisi, Meldola, Milan, Novara, Parma, Pavia
2019-08-27
Active, closed
Dizal Pharmaceuticals
Phase 1/2
315
Aviano, Catania, Florence, Meldola, Milan, Parma, Ravenna, Reggio Emilia
2019-07-09
Active, closed
Bristol-Myers Squibb
Phase 3
437
Brescia, Arezzo, Aviano (PN), Milan, Parma, Roma
2019-06-21
Recruiting
Hospices Civils de Lyon
Observational
3,500
Milan, Palermo, Parma
2019-02-25
Active, closed
Janssen Research & Development, LLC
Phase 3
765
Faenza, Milan, Naples, Padova, Parma, Perugia, Pisa, Roma
2019-01-25
Active, closed
AstraZeneca
Phase 2
367
Avellino, Florence, Milan, Orbassano, Padova, Parma, Perugia, Peschiera del Garda
2019-01-09
Active, closed
AbbVie
Phase 2
270
Bologna, Meldola, Milan, Naples, Rome, Orbassano, Avellino, Parma
2018-10-10
Active, closed
AstraZeneca
Phase 3
730
Brescia, Milan, Orbassano, Parma, Roma, Rozzano, Terni
2018-09-27
Active, closed
AstraZeneca
Phase 3
1,246
Arezzo, Milan, Naples, Orbassano, Parma, Pavia, Roma, Terni
2018-09-27
Recruiting
Scaffold in Emilia Romagna and in the MAGIC Network
NCT03327961Coronary Artery Disease
University Hospital of Ferrara
Observational
1,111
Agrigento, Treviglio, Bologna, Savigliano, Cona, Forlì, Modena, Parma
2017-12-02
Active, closed
Pfizer
Phase 3
296
Catania, Monza, Milan, Rozzano, Perugia, Pordenone, Parma, Roma
2017-04-27
Active, closed
Acerta Pharma BV
Phase 3
635
Bologna, Milan, Palermo, Parma, Pavia, Reggio Emilia, Rozzano, Turin
2017-04-05
Active, closed
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
NCT02716116Carcinoma, Non-Small-Cell Lung
DrugMobocertinib
Takeda
Phase 1/2
334
Milan, Parma
2016-06-16
Active, closed
Physica CR and Physica PS Clinical Trial
NCT02766231Knee Osteoarthritis
Limacorporate S.p.a
Observational
157
Milan, Parma
2016-02
Active, closed
Acerta Pharma BV
Phase 3
535
Alessandria, Aviano, Brescia, Florence, Meldola, Milan, Parma, Ravenna
2015-06-26
Active, closed
Eli Lilly and Company
Phase 3
453
Catania, Genova, Livorno, Parma, Rome
2014-10-03
Active, closed
AbbVie
Observational
1,446
Milan, Rome, Bologna, Messina, Naples, Palermo, Parma, Pescara
2014-08-28
Recruiting
Jules Bordet Institute
Not applicable
1,000
Biella, Bolzano, Carpi, Genova, Legnago, Milan, Parma, Pavia
2014-04
Active, closed
AstraZeneca
Phase 3
510
Bari, Genova, Livorno, Milan, Naples, Orbassano, Parma, Perugia
2013-09-25
Recruiting
Italian Network MDS Registry
NCT02808858Myelodysplastic-Myeloproliferative Diseases
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Observational
10,000
Alessandria, Ancona, Genova, Parma, Rionero in Vulture, Candiolo, Torino, Asti
2013-09
Recruiting
Azienda Ospedaliero-Universitaria di Parma
Observational
1,000
Milan, Palermo, Parma, Urbino, Bologna, Carrara, Genova, Naples
2010-09
Recruiting
Esteve Pharmaceuticals, S.A.
Observational
500
Ancona, Bolzano, Brescia, Florence, Genova, Naples, Parma, Province of Macerata
2008-12-09
Active, closed
Genentech, Inc.
Phase 2
378
Potenza, Catanzaro, Naples, Meldola, Parma, Aviano (PN), Udine, Milan
2008-10-16
Rows per page Showing 1–141 of 141
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-italy/city/parma

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 141 of those studies with a site in Parma.

How many clinical trials are recruiting in Parma?

60 of the 141 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 5 have not yet opened recruitment, 75 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Parma), 141 studies
PhaseStudiesRecruitingShare
Phase 3611543.3%
Observational322022.7%
Not applicable221515.6%
Phase 21459.9%
Phase 2/3543.5%
Phase 1/2412.8%
Phase 4201.4%
Phase 1100.7%

Most active sponsors

Lead sponsors with the most studies (Parma)
Lead sponsorStudiesRecruiting
AstraZeneca163
Azienda Ospedaliero-Universitaria di Parma1411
Hoffmann-La Roche81
Bristol-Myers Squibb63
University of Parma53
Azienda USL Reggio Emilia - IRCCS31
Bayer31
Boehringer Ingelheim31
Eli Lilly and Company31
IRCCS Azienda Ospedaliero-Universitaria di Bologna33
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.